Posted originally on the conservative tree house on October 19, 2022 | Sundance
The CDC’s Advisory Committee on Immunization Practices (ACIP) is scheduled to decide Thursday whether or not to include COVID-19 vaccinations in their pediatric immunization schedule. For most parents this quietly organized committee meeting is coming as a surprise. [ACIP Agenda Here]
Many states require following the CDC guidance as part of their school vaccine requirements. The substantively untested mRNA vaccine for children is quite controversial; however, as noted by some alternative media sources there is a benefit to Big Pharma in the approval. Mandated immunizations provide liability protection for the pharmaceutical companies that manufacture them, and the CDC is essentially a government arm of those same companies.
Fox News host Tucker Carlson used his widely watched broadcast to raise awareness of the meeting. {Direct Rumble Link} – WATCH:
And parents across the nation are demonstrating their lack of trust in the experimental mRNA vaccines issued under emergency use authorization, with only about 2% of children under 5 and less than one-third ages 5 to 11 having been fully immunized.
Nevertheless, the CDC is poised to address the “vaccine hesitancy” and the pharmaceutical companies’ lack of permanent liability with one vote.
Approval not only would make it more likely that states will mandate COVID-19 shots to attend public school, it could grant permanent legal immunity to vaccine makers Pfizer and Moderna along with another profit windfall, health scientists are warning. (read more)
While the CDC guidelines for pediatric vaccination schedules doesn’t technically force states to follow the federal guidance, many states defer to the CDC and require their school districts to follow the guidelines. As a result, adding the mRNA COVID vaccine to the federal immunization schedule would mean many parents would have to give their child the vaccine in order to comply with state requirements.
There are several studies and a growing number of pediatric doctors who are concerned about the safety of the mRNA vaccine in a childhood group who are not at high risk from the virus itself. For children and young adults, the benefit of the vaccination is potentially outweighed by the harm it may cause. Mandating the COVID-19 vaccine in children is extremely concerning, albeit beneficial to Big Pharma.
Arizona gubernatorial candidate Kari Lake was asked about the issue on Wednesday and responded that she would not support adding the mRNA vaccination to the state requirement. {Direct Rumble Link} – WATCH:
Posted originally on the conservative tree house on September 6, 2022 | Sundance
Less than 24 hours after making a weird proclamation that he “defeated Big Pharma,” Joe Biden introduces a new annual vaccine:
[White House] – This week, we begin a new phase in our COVID-19 response. We are launching a new vaccine – our first in almost two years – with a new approach. For most Americans, that means one COVID-19 shot, once a year, each fall. Starting this week, at tens of thousands of convenient pharmacies, doctor’s offices, and community health centers, and other places, Americans age 12 and older can go get this new fall COVID-19 vaccine. The new vaccines provide the strongest protection from the new Omicron strain of the COVID virus, which did not exist when the original vaccine was developed. As the virus continues to change, we will now be able to update our vaccines annually to target the dominant variant.
Just like your annual flu shot, you should get it sometime between Labor Day and Halloween. It’s safe, it’s easy to get, and it’s free. Go to Vaccines.gov to find a location near your home or work.
It’s simple, and it’s easy to understand: If you are vaccinated and 12 and older, get the new COVID-19 shot this fall. This once-a-year shot can reduce your risk of getting COVID-19, reduce your chance of spreading it to others, and dramatically reduce your risk of severe COVID-19. Winter is not that far away. The past two years, we have seen COVID-19 cases and deaths soar. It does not have to be that way this year. If you are 12 and older, go get your new COVID-19 shot this fall. (LINK)
The International Journal of Environmental Research and Public Health published a study that found the lockdowns were deadly. In fact, the lockdowns were 20 times more deadly than COVID. The lockdowns were a mass human experiment. There was no evidence that indicated this method would be effective. We saw the impact that the lockdowns had on the global economy, but their effects on the human mind are now coming to light.
“The comparative analysis of different countries showed that the assumption of lockdowns’ effectiveness cannot be supported by evidence—neither regarding the present COVID-19 pandemic, nor regarding the 1918–1920 Spanish Flu and other less-severe pandemics in the past. The price tag of lockdowns in terms of public health is high: by using the known connection between health and wealth, we estimate that lockdowns may claim 20 times more life years than they save. It is suggested therefore that a thorough cost-benefit analysis should be performed before imposing any lockdown for either COVID-19 or any future pandemic.”
Forcing people into isolation is a tactic used in prison for punishment. Everyone’s mental health suffered as life as we knew it simply halted. People lost their livelihoods, were unable to see loved ones, and were forced to tip toe around society when they emerged for essentials. Kids fell behind in school and socialization. One of the most deadly aspects, however, was the way healthcare facilities managed COVID patients.
“The lockdown policies had a direct side effect of increasing mortality. Hospitals in Europe and USA were prepared to manage pretty small groups of highly contagious patients, while unprepared for a much more probable challenge—large-scale contagion. As a result, public health care facilities and nursing homes often became vehicles of contamination themselves—to a large extent because of the lockdown-based emergency policy implementation.”
Governor Cuomo of New York tried to hide the deaths that occurred in nursing homes. Over 9,000 infected patientsin New York alone were discharged from hospitals and sent into nursing homes. This resulted in thousands of unnecessary deaths. No one was ever held responsible for that decision.
“Another comparison can be made if we remember that the average age of people dying of COVID-19 was around 80, with 3–6 QALY per death lost. Therefore, 500,000 QALY are equivalent to roughly 100,000 COVID-19 deaths. Even if we assume that lockdowns saved 1.5 daily deaths per million [20] for a whole year (365 days), after multiplying by 9.2 million (population of Israel) we arrive at about 5000 lives saved—just about 5% of the lockdowns’ human cost. In other words, it can be estimated that even if the lockdowns saved some lives, in the long term they killed 20 times more.”
There is no evidence to suggest that the lockdowns were effective. Even if the lockdowns worked as intended, they directly caused more deaths than they were intended to prevent.
American household has reached a new high, according to a report by the Federal Reserve Bank of New York. Total household debt has surpassed $16 trillion for the first time in American history. Americans have taken on $2 trillion in additional debt since the pandemic. Aggregate household debt balances rose by $312 billion in Q2 2022 alone, marking a 2% increase from Q1.
Mortgages were the largest contributing factor to the post-pandemic uptick after rising by $207 billion to $11.39 trillion. Americans have been relying more on credit to make purchases amid inflation, and credit card balances have spiked by $46 billion last quarter. Non-housing balances saw the largest uptick since 2016 after increasing by $103 billion. Auto loans saw a $33 billion rise as the cost of autos remained at a high.
Delinquency on debt “increased modestly” in all categories. Around 95,000 people faced bankruptcy in Q2 2022, which is still near historic lows. Of the $758 billion in new mortgage debt accumulated in the last quarter, 65% is held by people with credit scores over 760. Outstanding student loan debt reached $1.59 trillion last quarter, 5% of which was delinquent.
People may be able to pay off their debt now, but as inflation and interest rates rise, that will become increasingly difficult. While mortgage debt is no cause for concern, the over-reliance on credit purchases will not help Americans lower debt. Inflation must come down for the people to maintain their quality of life.
Dr. Anthony Fauci is relentless. Biden told us the fable of the winter of death and destruction last year. Now Fauci is warning that people are “going to get into trouble” if they’re not vaccinated and boosted by the fall and winter months.
After hearing of the countless side effects and realizing the vaccination does not prevent infection or transmission, most Americans do not want a booster. The Kaiser Family Foundation found that 70% of Americans, 228 million people, are currently not up to date on their vaccinations. Only 48.4% of Americans (children over five included) opted for a booster shot.
Fauci claims people should do it for their “community.” Why? I could have Moderna, Pfizer, J&J, and the rest injected into me, and it still would not prevent me from being prone to transmitting the virus. Fauci himself caught COVID, and even Biden continued to work and failed to isolate after testing positive for the virus. Fauci’s fears are falling on deaf ears as people are becoming aware of the truth – the vaccines do not work.
Posted originally on the conservative tree house on August 7, 2022 | sundance
The glove has been thrown down, as New York Governor Kathy Hochul enters the national contest for political inauthenticity.
Prior to today, California Governor Gavin Newsom was the closest competitor within striking distance of Elizabeth Warren’s “I’m a git me a beer” moment. However, the assembly of advisors that guide team Hochul have now entered the contest with Hochul’s visual tweet earlier today:
Unfortunately, there are several progressive demerits which may keep Hochul from achieving maximum pander points. The biggest issue is beef, no longer an acceptable food product amid the left-wing judges. A tray of sustainable algae cakes would have been better. However, to be fair, there are rumors team Hochul was using ‘cricket burgers‘, which could offset the carbon demerits as presented by grilling.
Governor Hochul’s entry in the inauthenticity contest is certainly not the first one we will see this election year. However, she has proudly planted her flag.
Posted originally on the conservative tree house on August 7, 2022 | sundance
George Stephanopoulos has a new hero not named Obama. Skipping both the red and blue pills in favor of Xanax and whiskey, a visually verklempt Stephanopoulos uses Dick Cheney as the introduction to the 2022 midterm election victory map. The last 3 seconds of this clip are funny as heck.
Pay no attention to the 67% of Americans who say things are getting even worse, and instead let’s cheer Dick Cheney and baby killing, after all – they are weirdly connected in a way. Thus, George has figured the new DNC strategy. Brilliant.
Geert Vanden Bossche, DVM, PhD General Manager at Voice for Science and Solidarity | The biggest challenge in vaccinology: Countering immune evasion posted originally on TS New on Aug. 1, 2022
Exposure of a highly C-19 vaccinated population to monkeypox virus (MPV) spilling over from an animal reservoir promotes asymptomatic human-to-human transmission in susceptible sexual minority communities (SMCs). MPV infection in SMCs could therefore evolve more infectious viral variants that spread to all parts of a highly C-19 vaccinated population and thereby prevent establishment of herd immunity
Increasing numbers of outbreaks of human monkeypox have been reported from across central and west Africa over the last 3-4 decades. Zoonotic infection with MPV in the current setting of limited smallpox vaccination and little orthopoxvirus immunity[1] in several parts of the world renders human populations more susceptible to contracting monkeypox disease. MPV has therefore been considered a well-suited candidate for a global epidemic.
As productive poxvirus infection is mostly symptomatic and viral transmission almost exclusively occurs through close contact with an infected animal or person or via virus-contaminated objects, such as bedding or clothing, it has been generally acknowledged that naturalepidemic outbreaks in humans can largely be contained through basic infection-prevention measures (including good hygiene practices). Unless the viral infection rate is high (e.g., in densely populated areas and poor [environmental] hygiene conditions), it is difficult to imagine how MPV could evolve to adapt to the human population, let alone how it could ignite a multi-country epidemic or even a pandemic in countries where MPV is not an endemic zoonosis. Pandemics typically occur with pathogens that cause so-called acute self-limiting infection, meaning that they have the potential to spread asymptomatically before inducing a type of natural immunity that prevents productive infection upon subsequent exposure and, therefore, generates herd immunity. Whereas until recently many still tended to believe that the threat of a globally spread MPV was a myth, cases are now being reported globally (at least in all highly C-19 vaccinated parts of the world) to the extent that WHO has now declared MPV a health emergency of international concern—all of this has happened within just a few months. This does not provide enough time for population-level innate immunity to become sufficiently trained to turn MPV infection, which is typically symptomatic (so-called ‘acute self-limiting viral disease’, ASLVD) into an infection that is predominantly asymptomatic (so-called ‘acute self-limiting viral infection’, ASLVI) and can therefore much more easily spread between people. On the other hand, adaptation of a virus to a new host population never implies natural selection of less infectious viral variants, on the contrary. If neither viral evolution nor immune training is responsible for shifting symptomatic into asymptomatic viral transmission (thereby allowing MPV to spread more efficiently from person-to-person and eventually become a pandemic), other non-evolutionary disease-mitigating influences must be considered. As spread of MPV is now particularly expanding in countries with high C-19 vaccine coverage rate and as ASLVD-enabling viruses that are predominantly transmitted through close contact do not spread rapidly, there must be a link between the type of population-level immunity in highly C-19 vaccinated populations and the rapid expansion in prevalence of MPV cases. It’s also important to note that—so far— MPV disease symptoms in these populations have been rather ‘mild’ and predominantly manifest in individuals from the gay and bisexual male community. This already suggests that sexual contact, especially when the latter is at risk of traumatizing the skin or mucosa (e.g., in case of anogenital intercourses), facilitates symptomatic MPV infection.
While I cannot unambiguously prove this, I strongly believe that the sudden emergence of a significant number of (mild) cases of MPV in highly C-19 vaccinated countries is not purely coincidental but related to enhanced activation of broadly reactive, MHC-unrestricted CD8+ T cells in vaccinees. I have previously reported on how a universal CTL (cytotoxic T lymphocyte) epitope can facilitate elimination of host cells infected with ASLVI- or ASLVD-enabling glycosylated viruses and thereby allow recovery from disease, however without inducing immunologic memory (https://www.voiceforscienceandsolidarity.org/scientific-blog/epidemiologic-ramifications-and-global-health-consequences-of-the-c-19-mass-vaccination-experiment). More specifically, MHC-unrestricted CD8+ T cells that now increasingly prevent C-19 disease in healthy vaccinees are the same as those required to abrogate productive infection with other glycosylated viruses that have evolved reduced susceptibility to our innate immune system[2], including poxviruses (https://www.frontiersin.org/articles/10.3389/fimmu.2021.740223/full).
Given the enhanced immune activation of pathogen-nonspecific CTLs[3] in C-19 vaccinees, MPV infection in C-19 vaccinees is likely to become abrogated at an early stage of productive infection, thereby dampening productive MPV infection and potentially causing asymptomatic/ mild infection in sexual minority communities (SMCs) of a highly C-19 vaccinated population. Consequently, MPV infection may even fail to induce MPV-neutralizing antibodies (Abs) in vulnerable[4], C-19-vaccinated individuals that are immunologically naïve to MPV (i.e., today persons younger than 45 to 55 years of age, depending on the country). However, it is reasonable to assume that asymptomatic MPV infection may elicit short-lived, low affinity anti-MPV Abs in these individuals (as has, for example, been reported in case of asymptomatic infection with SARS-CoV-2 (SC-2; https://www.medrxiv.org/content/10.1101/2020.06.22.20137141v2.full.pdf). As asymptomatic infections promote viral transmission within these minority communities, the infection rate of MPV in this vulnerable subpopulation is likely to grow over time. This rise in viral infection rate will subsequently increase the likelihood for previously asymptomatically infected persons from SMCs to become re-infected while titers of their short-lived, low-affinity anti-MPV antibodies are still relatively high. Binding of such low-affinity, non-neutralizing Abs to the virus is thought to enhance viral infectiousness and could thereby cause a disease outbreak in these communities. It is, therefore, reasonable to expect that the proportion of vulnerable individuals who develop virus-neutralizing Abs (i.e., upon their recovery from MPV disease[5]) in the C-19 vaccinated part of the population will increase over time. However, in vulnerable, non-C-19-vaccinated individuals, trained innate immune cells (i.e., NK cells) are likely to prevent MPV from breaking through this first line of immune defense and would therefore largely prevent priming of virus-neutralizing Abs. For the time being, symptomatic manifestations in highly C-19 vaccinated populations are predominantly mild and mostly occurring in SMCs. This suggests that even in cases of symptomatic infection, viral clearance via innate or adaptive cytolytic immune cells (in the case of non-C-19 vaccinated or C-19 vaccinated, respectively) is still effective enough to prevent more problematic symptomatology in most cases.
Rising virus-neutralizing Ab titers can only prevent monkey disease but not viral infection. Hence, re-exposure to MPV of C-19 vaccinated individuals who are in the process of seroconverting promotes natural selection of more infectious MPV immune escape variants while fostering asymptomatic transmission and thereby contributing to a further rise in viral infectious pressure. Due to the steadily growing infection rate in SMCs of highly C-19 vaccinated populations, the overall MPV-neutralizing Ab response in these communities is likely to exert suboptimal immune pressure on viral infectiousness and can therefore be expected to drive dominant circulation of naturally selected, more infectious MPV immune escape variants. Based on all the above, the enhanced infection rate mediated by asymptomatic transmission of MPV in SMCs of highly C-19 vaccinated populations is likely to increase the probability of adaptive evolution of MPV in these communities. It is, therefore, critical to monitor the selective landscape of MPV as unfolded in SMCs of highly C-19 vaccinated populations in order to verify whether the evolutionary trajectory is shifting towards promoting natural selection and expansion of immune escape variants that are more infectious (as is smallpox virus, for example).
Vaccination of vulnerable groups (SMCs) against MPV is likely to accelerate adaptive evolution of MPV in highly C-19 vaccinated populations and could thereby raise the incidence of (severe) MPV disease in vulnerable subsets of non-C-19-vaccinated individuals and ignite multi-country epidemics of MPV in non-C-19-vaccinated animal and human populations that are immunologically naïve to orthopoxvirus
Several countries are now about to start vaccination campaigns targeted at people who are at risk of contracting monkeypox disease using live attenuated, replication-incompetent smallpox vaccine. Both, individuals from SMCs engaging in high-risk sexual behaviors for MPV infection and close contacts of monkeypox cases (including very young children, pregnant women, elderly or immunocompromised individuals) are eligible for MPV vaccination (https://www.ecdc.europa.eu/sites/default/files/documents/Monkeypox-multi-country-outbreak.pdf). Live attenuated, replication-incompetent orthopox (e.g., smallpox) vaccines prime virus-neutralizing Abs in the vast majority of both vaccinated and non-vaccinated individuals (i.e., individuals < 50y). However, unlike live attenuated replication-competent orthopox vaccines[6], they do not train cell-based innate immunity. There can be no doubt that vaccination in the context of more infectious circulating MPV variants will further promote natural selection and dominant propagation of even more infectious immune escape variants and thereby allow MPV to evolve into a human pathogen exhibiting an even higher level of infectiousness (comparable to smallpox?). This situation is reminiscent of that which has been responsible for driving adaptative evolution of more infectious SC-2 (SARS-CoV-2) variants following C-19 mass vaccination campaigns. The evolutionary dynamics of MPV will only be expedited when vaccine coverage rates grow; they could eventually modify the current mode[7] and course of chain of MPV transmission such as to asymptomatically spread to all parts of a homogenously mixed, highly C-19 vaccinated population. This would increase the risk for C-19 unvaccinated subjects to contract MPV disease, especially for those who are particularly vulnerable to MPV disease because of Ab-mediated enhancement of viral infectiousness or enhanced susceptibility to MPV infection due to risky (sexual) behavior (see further below). Because of asymptomatic transmission, highly C-19 vaccinated populations would serve as a human reservoir of more infectious MPV immune escape variants.
Spill-over of more infectious MPV variants to populations that are immunologically naïve to orthopoxvirus is likely to trigger epidemics of MPV in poorly C-19 vaccinated countries
It is reasonable to assume that populations which do not ‘benefit’ from hyperactivation of cytotoxic CD8+ T cells will become more susceptible to productive infection with new, more infectious MPV variants (https://www.voiceforscienceandsolidarity.org/scientific-blog/epidemiologic-ramifications-and-global-health-consequences-of-the-c-19-mass-vaccination-experiment). This applies, for example, to several different animal populations as well as to human populations in poorly C-19 vaccinated countries (e.g., in Africa). Asymptomatic infections in highly vaccinated C-19 countries are likely to promote spill-over events involving transmission of more infectious MPV variants from these highly C-19 vaccinated human reservoirs to vertebrate animals (possibly even including livestock) and poorly C-19 vaccinated human populations that are immunologically naïve to orthopoxvirus. Asymptomatic transmission of more infectious MPV variants can also become problematic for the C-19 unvaccinated in highly C-19 vaccinated countries, particularly for C-19 unvaccinated children and vulnerable people (e.g., part of SMCs) who are immunologically naïve to orthopoxvirus.
In young children, rapid re-infection subsequent to previous asymptomatic MPV infection by more infectious MPV variants is likely to entail a rise in cases of Ab-dependent enhancement of MP disease[8] whereas risky sexual behavior renders individuals from SMCs more susceptible to viral infection. One can therefore expect the incidence rate of monkeypox disease to increase in both, non-C19-vaccinated children and SMC members.
Previous vaccination with smallpox (i.e., cowpox) vaccines will likely improve protection from MPV disease in the non-C-19-vaccinated but not in the C-19 vaccinated.
While recall of Abs induced by vaccination against smallpox virus in the past will provide an additional layer of natural immunity in the unvaccinated, repetitive recall of Spike (S)-specific infection-enhancing Abs[9] in C-19 vaccinated individuals by circulating SC-2 variants will allow the latter to outcompete other glycosylated pathogens for internalization into mucosa-resident dendritic cells, thereby reducing or potentially even preventing recall of previously smallpox vaccine-induced Abs. This would imply that older (> 45-50y) C-19 unvaccinated individuals are likely to benefit from their smallpox-vaccination in the past whereas their C-19 vaccinated peers may not. However, as already mentioned, the infection can be expected to be largely asymptomatic/ mild in the vast majority[10] of vaccinated and unvaccinated individuals in highly C-19 vaccinated populations, even in the absence of previous smallpox vaccination.
No child should be vaccinated against monkeypox during this C-19 pandemic
But even replication-competent smallpox vaccines can put the child’s health at risk. Akin to all other live attenuated & replication-competent vaccines (e.g., childhood vaccines), these vaccines are known to come with a risk of side-effects:
“Health complications can occur after receiving the vaccine, and the risk of experiencing serious side effects must be weighed against the risk of experiencing a potentially fatal smallpox infection. The vaccine may cause myocarditis and pericarditis, which are inflammation and swelling of the heart and surrounding tissues and can be very serious. Based on clinical studies, myocarditis and/or pericarditis occur in 1 in 175 adults who get the vaccine for the first time” (https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000-smallpox-vaccine-questions-and-answers).
Stated bluntly, vaccination of young children against MPV is at risk of provoking life-threatening disease.
Overall conclusion
The vast majority of C-19 vaccinees and C-19 unvaccinated individuals in highly C-19 vaccinated populations develop asymptomatic (or very mild) infection upon exposure to MPV. However, close and disruptive physical contact may promote viral entry through broken skin/ mucosa and is therefore more likely to cause symptomatic infection. Whereas strong training of cell-based innate immunity is likely to prevent productive infection of C-19 unvaccinated persons in highly C-19 vaccinated populations and contributes to herd immunity, hyperactivated cytolytic CD8+ T cells in C-19 vaccinated individuals can only enhance abrogation of productive infection, resulting in substantial mitigation of disease symptoms.
Due to the current advanced stage of the evolutionary trajectory of the C-19 pandemic in highly C-19 vaccinated SMCs, MPV is likely to evolve more infectious/ pathogenic variants. Public health authorities in several highly C-19 vaccinated countries have now started rolling out MPV vaccination campaigns targeted at SMCs. MPV vaccination in the ‘at risk’ groups typically use live attenuated, non-replicating smallpox vaccines. Although these vaccines are much less problematic in terms of vaccine-induced side effects (they have even been approved for use in immunocompromised or immunodeficient people), they can only prevent orthopox (including smallpox) disease—not productive infection. As the type of protection conferred by these vaccines is solely based on the induction of antigen-specific, virus-neutralizing Abs, MPV vaccination programs using this type of vaccines will inevitably expedite adaptive evolution of MPV and hence, further promote dominant circulation of more infectious immune escape variants. Consequently, even small-scale deployment of live attenuated, non-replicating orthopox vaccines targeted at preventing disease in vulnerable individuals are highly problematic in that they have the potential to rapidly turn highly C-19 vaccinated populations into a human reservoir for asymptomatic transmission of more infectious MPV variants to poorly C-19 vaccinated populations that are immunologically naïve to orthopoxvirus. Viral transmission from these reservoirs is therefore at risk of igniting multi-country epidemics in poorly C-19 vaccinated countries while increasing the risk of Ab-dependent enhancement of disease in young C-19 unvaccinated children and individuals at high risk of exposure to MPV (due to risky behavior) living in highly C-19 vaccinated countries.
Given the current epidemiologic situation, mandatory vaccination against monkeypox cannot be justified, regardless of C-19 vaccination status. In C-19 vaccinated populations, current vaccination campaigns will only promote further expansion of more infectious MPV variants. But even in non-C19-vaccinated countries, vaccination is not a reasonable option. This is because poxvirus epidemics do not generate herd immunity sensu stricto[12] and prevention, therefore, of world-wide poxvirus epidemics is only possible when the virus can be eradicated. However, eradication is only feasible provided there are no asymptomatic reservoirs and a global mass vaccination program is conducted with vaccines that are capable of preventing productive infection. The first condition is obviously not fulfilled since highly vaccinated countries now serve as asymptomatic reservoirs for MPV. The second condition cannot be fulfilled either since this would require usage of replication-competent vaccines, ideally in a pre-exposure prophylactic setting (or at least within a few days after suspected exposure). However, even replication-competent smallpox vaccines would not enable protection from productive infection by more infectious MPV immune escape variants for the latter will not be a good match for the vaccinal Abs and could, therefore, expedite propagation of more infectious variants in non-C-19 vaccinated populations too. Furthermore, side-effects caused by the existing replication-competent smallpox vaccines may raise additional concerns in regard of vaccine safety.
In conclusion, no C-19 unvaccinated person should engage in sexual behavior that is at risk of enhancing MPV infectiousness (e.g., anogenital intercourses) or be vaccinated with zoonotic orthopoxvirus types once human-to-human transmission of antigenically shifted (i.e., more infectious) MPV variants is occurring!
The current MPV pandemic is to be considered an indirect consequence of the unfortunate C-19 mass vaccination program and does not yet constitute a public health emergency of international concern. However, each vaccination program that uses non-replicating vaccines targeted at immunologically naïve ‘at risk’ communities to fight ASLVI-enabling glycosylated viruses[13] will expedite the expansion in prevalence of more infectious immune escape viral variants. This is why the MPV vaccination campaigns that are currently kicked off are not only likely to have a detrimental impact on individual health (particularly in C-19 unvaccinated children and vulnerable people) but should also be considered at risk of provoking a true public health emergency of international concern.
However, as far as highly C-19 vaccinated countries are concerned, the evolution of MPV towards establishing an asymptomatic reservoir of more infectious MPV variants is merely a ‘side-effect’ of the ongoing evolutionary trajectory of SC-2 in these countries. I therefore predict that the imminent detrimental health consequences of the C-19 mass vaccination program will soon obviate the need for further speculation on how the MPV pandemic/ multi-country epidemic is going to evolve in industrialized countries and, therefore, in third-world countries.
POSTSCRIPTUM
Vaccination of vulnerable groups against zoonotic influenza virus (MPV) in a highly C-19 vaccinated population will drive adaptive evolution of zoonotic influenza virus and ignite multi-country epidemics in C-19 unvaccinated countries
The immunological mechanisms underlying asymptomatic transmission of MPV from highly C-19 vaccinated populations to immunologically orthopoxvirus-naïve, C-19 unvaccinated individuals or poorly C-19 unvaccinated populations also largely apply to a zoonotic influenza virus. This is to say that vaccination (with a non-replicating zoonotic flu vaccine) of a C-19 vaccinated subpopulation that is at high risk of contracting zoonotic influenza infection is prone to further promoting the expansion of zoonotic flu virus and causing (severe) influenza disease in vulnerable people from the C-19 unvaccinated part of the population.
Which individuals are to be considered vulnerable to zoonotic influenza virus?
Whereas orthopoxviruses originating from various animal species induce cross-neutralizing Abs, influenza viruses from animal species do not induce broadly cross-neutralizing Abs. Individuals who received smallpox (i.e., cowpox-based) vaccines in the past are therefore not prone to developing Ab-dependent enhancement of viral infectiousness upon subsequent exposure to MPV. However, asymptomatic human-to-human transmission of an antigenically shifted influenza variant spilling over from an animal reservoir (e.g., birds) may become particularly problematic in individuals who have previously recovered from productive infection with a common seasonal influenza virus type or who have previously been vaccinated against predominantly circulating influenza virus types (i.e., primarily the elderly and people with co-morbidities are who are otherwise immune suppressed). Zoonotic infection of these individuals with an antigenically shifted viral variant (most likely avian influenza) will likely lead to more and more cases of Ab-dependent enhancement of influenza disease[14] in humans. However, severe disease is unlikely to occur due to trained cell-based innate immunity (in C-19 unvaccinated persons) or cell-based adaptive immunity (in C-19 vaccinated persons). Should public health authorities recommend vaccination of this vulnerable group against the zoonotic influenza virus (most like, avian influenza virus), we will undoubtedly witness circulation of more infectious variants in highly vaccinated populations, resulting in enhanced rates of disease predominantly in C-19 unvaccinated children (because of a higher chance of re-infection shortly after previous exposure) and individuals who have previously been primed with common (seasonal) influenza virus types.
Similar to the epidemic predictions made for MPV, asymptomatic transmission of zoonotic influenza (most likely avian influenza) from highly C-19 vaccinated populations will likely give rise to multi-country epidemics of zoonotic influenza in poorly C-19 vaccinated populations that are immunologically naïve to the transmitted zoonotic influenza virus.
Similar also to the risks associated with MPV vaccination of young children, immunization of young children with any type of zoonotic influenza vaccine is at risk of causing (severe) zoonotic influenza disease (i.e., in the case of replication-competent vaccines) or immunopathologies (i.e., in the case of replication-incompetent vaccines).
In conclusion, no C-19 unvaccinated person should be vaccinated with common (seasonal) or zoonotic influenza virus types once human-to-human transmission of antigenically shifted (i.e., more infectious) influenza variants is occurring!
References
1. Populations aged < 50y have not been vaccinated in the past against smallpox. The smallpox vaccine uses live attenuated, replication-competent cowpox (vaccinia) virus and largely protects against monkeypox disease.
2 Infections with these viruses typically cause acute self-limiting viral disease
4 For the purpose of this manuscript, ‘vulnerable’ refers to individuals from sexual minority communities (SMCs), wherein SMCs refer to gay and bisexual male communities engaging in high-risk sexual behaviors for MPV infection (e.g., anogenital intercourses)
5 Disease in vulnerable, C-19 vaccinated individuals occurs when the virus breaks through the cytolytic immune defense provided by the hyperactivated CTLs
6 Regardless of safety concerns about potential side-effects, live attenuated, replication-competent orthopox vaccines will not be effective when used in highly C-19 vaccinated populations. This is because elimination of MPV- infected cells by cytotoxic innate or adaptive immune cells (i.e., trained innate NK cells or CTLs in the non-C19- vaccinated or C-19 vaccinated, respectively) will largely prevent ‘vaccine take’.
7 Enhanced intrinsic infectiousness could even enable airborne transmission (e.g., via particle/ droplet aerosol) as in the case of smallpox
8 Re-infection with MPV in the presence of non-neutralizing, low-affinity anti-MPV Abs enhances viral infectiousness and, therefore, disease in young, C-19 unvaccinated children
10 The additional protective effect of past vaccination with smallpox vaccines might predominantly benefit the elderly (> 65 y) and vulnerable people.
12 Herd immunity sensu stricto relates to a level of naturally induced, protective immunity that has been established in the majority of the population and is high enough to protect the remainder of that population by virtue of diminished infectious transmission.
13 Although monkey pox is an ASLVD, it can be considered an ASLVI when spreading in a highly C-19 vaccinated population at this stage of the C-19 pandemic (i.e., due to hyperactivation of cytolytic CD8+ T-cells)
14 This is because the antigenically shifted immune escape variant from the animal reservoir will not properly match the vaccine-induced Abs.
Awaken With JP originally Published on Rumble on July 23, 2022
This week’s news includes everything from Biden shaking hands with the air again, Pelosi’s insider trading, and how they are trying to turn the US into a third world country! Here’s Lies You Can Trust…
Posted originally on the conservative tree house on August 6, 2022 | sundance
Every once in a while, you come across an article that seems like one thing but is actually another thing entirely. The NPR story of how “The U.S. made a breakthrough battery discovery — then gave the technology to China“, is one such article.
Several people sent this to us for opinion and review; however, the background of the article reveals something quite different. Then again, perhaps that’s exactly why NPR wrote it.
It is important to read the story as presented by NPR, because it is oddly written as if someone is trying to use the outlet to get out ahead of something else.
The issue surrounds a new product technology called a vanadium redox flow battery. Essentially the U.S. government funded scientists to develop an advanced battery that could store energy without degrading. After success, the technology was then sent to China for manufacturing. China then invested heavily in the product and used the technology to mass manufacture the battery for the global market. The United States is now behind in the product development and manufacture.
As the story is told in NPR, “the Chinese company didn’t steal this technology. It was given to them — by the U.S. Department of Energy. First in 2017, as part of a sublicense, and later, in 2021, as part of a license transfer.” Except that’s not what happened at all. There is some major ‘ass-covering’ in that false narrative.
The lead scientist working on the vanadium redox flow battery project was a man named Gary Yang. Mr. Yang was born in China and emigrated to the U.S. becoming a U.S. citizen. Yang worked with U.S. scientists to develop the technology and was funded by a multi-million research grant from the Dept of Energy.
After their initial success, according to NPR, “in 2012, Yang applied to the Department of Energy for a license to manufacture and sell the batteries.” The Dept of Energy license was granted, and Yang launched UniEnergy Technologies as the parent company to develop the commercial application of the product.
It’s 2012 and Gary Yang was now looking for investors and manufacturing in the commercial sector to produce the battery.
Here’s where it gets interesting…. According to Yang, “he couldn’t persuade any U.S. investors to come aboard. “I talked to almost all major investment banks; none of them (wanted to) invest in batteries,” Yang said in an interview, adding that the banks wanted a return on their investments faster than the batteries would turn a profit.” This is Yang’s justification for what he did next.
After he couldn’t find U.S. investors (which I will say up front seems like an excuse), Yang then took the technology to China to have them manufacture the product.
The Chinese embraced the technology, created entire manufacturing eco-systems around it and now corner the market on the technology behind vanadium batteries. However, giving the technology to China for manufacturing and development is a violation of the license Chang was given.
Yang even admits he knew it was not allowed. “Yang’s original license requires him to sell a certain number of batteries in the U.S., and it says those batteries must be “substantially manufactured” here. In an interview, Yang acknowledged that he did not do that.” Now we start to look a little more skeptically at the claims by Gary Yang, because a whole bunch of stuff just doesn’t add up.
As noted by NPR, five years after getting the license from the Dept of Energy, “in 2017, Yang formalized the relationship and granted Dalian Rongke Power Co. Ltd. an official sublicense, allowing the company to make the batteries in China.”
After China had fully developed the technology, they obviously no longer needed Gary Yang to go global with the product. As a result of what can only be considered as ‘getting cut out’, Yang -still holding the original DoE license- then turned to Europe.
Gary Yang not only sublicensed Chinese manufacturing, supposedly without DoE notification, in 2021 he sold the license to the Netherlands.
“In 2021, Yang transferred the battery license to a European company based in the Netherlands. The company, Vanadis Power, told NPR it initially planned to continue making the batteries in China and then would set up a factory in Germany, eventually hoping to manufacture in the U.S., said Roelof Platenkamp, the company’s founding partner.
Vanadis Power needed to manufacture batteries in Europe because the European Union has strict rules about where companies manufacture products, Platenkamp said. “I have to be a European company, certainly a non-Chinese company, in Europe,” Platenkamp said in an interview with NPR.”
Before moving on, let me recap because things are going to start making sense about why this story has some major ramifications. Also, don’t overlook the timing of events and keep in the back of your mind what you know about Hunter Biden (remember, ‘energy sector’ with no experience) and Biden’s deals with China being made in/around this same timeframe.
♦ 2006 – Pacific Northwest National Laboratory original grant. “It took six years and more than 15 million taxpayer dollars for the scientists to uncover what they believed was the perfect vanadium battery recipe.“
♦ 2012 – The lead scientist, Gary Yang, asks the Dept of Energy for a license. He then creates UniEnergy Tech.
♦ 2013/2014 – Unable to find investors in the U.S., Gary Yang enters a manufacturing and development agreement with China.
♦ 2017 – Gary Yang officially grants a sublicense to Dalian Rongke Power Co. Ltd in China.
♦ 2021 – Gary Yang then sells his license to Vanadis Power in the Netherlands.
Tell me again how this NPR sentence makes sense: “the Chinese company didn’t steal this technology. It was given to them — by the U.S. Department of Energy. First in 2017, as part of a sublicense, and later, in 2021, as part of a license transfer.”
Do you see anywhere in this reformatted outline where the U.S. Dept of Energy gave the technology to anyone, except Gary Yang?
The only entity responsible for transferring the technology to China was Gary Yang.
Now, with all that in mind, check out the date on the picture that NPR uses in their article:
2015
Keep the guy on the left, Imre Gyuk, in mind as we move forward. Note the date of “2015” with Imre Gyuk and Gary Yang. They are standing together.
Remember in the NPR article, the baseline for why Yang took the technology to China was that he couldn’t find investors to manufacture in the United States.
The vanadium battery license in question would have come from Imre Gyuk’s office. Now, in addition to being the Director of Energy Storage Research in the Office of Electricity, of the Dept of Energy, Gyuk also held another role: “As part of the program he also supervises the $185M ARRA stimulus funding for Grid Scale Energy Storage Demonstrations” {Citation}
The ARRA funds referenced were the Obama-era stimulus funds; the American Recovery and Reinvestment Act funds; the shovel ready jobs funds. Yet, Gary Yang cannot find investors?
Citation from 2014: “It’s not a given that lithium-ion batteries are the best batteries for electric cars, or for electrical grid storage. Other types of batteries today show promise, most of which you’ve never heard of: vanadium redox flow, zinc-based, sodium-aqueous and liquid-metal. Businesses looking to invest in batteries are deciding between these technologies and more. Market players will weigh the different technologies’ cost of manufacture, durability, usefulness.” {Citation} But Gary Yang couldn’t find U.S. investors?
Citation from 2014: “The forever battery.” A Silicon Valley startup run by old-school technologists has invented an energy storage device that could take an entire neighborhood off the grid. This magic box is called a Vanadium redox flow battery. {Citation} But Gary Yang couldn’t find U.S. investors.
Citation from 2016: “Cost-effective, reliable, and longer-lived energy storage is necessary to truly modernize the grid,” said Dr. Imre Gyuk, energy storage program manager for DOE’s Office of Electricity Delivery and Energy Reliability, of UET’s system. “As third-generation vanadium flow batteries gain market share, it is essential to increase our understanding of storage value and optimization to accelerate adoption of integrated storage and renewable energy solutions among utilities.” {Citation} But Gary Yang couldn’t find U.S. investors. {Here’s another Citation}
Citationfrom 2018: “On January 23, 2018, the Chinese Academy of Sciences hosted a meeting on energy storage with distinguished guests Dr. Imre Gyuk, director of energy storage research at the United States Department of Energy, and Dr. Gary Yang, CEO of UniEnergy Technologies. Dr. Gyuk and Dr. Yang were met by China Energy Storage Alliance Chairman and the Chinese Academy of Sciences Institute of Engineering Thermophysics Deputy Director Chen Haisheng, China Energy Storage Alliance Deputy Chairman and Beijing Puneng General Manager Huang Mianyan, and CNESA Standing Council Representative and general manager of State Grid Electric Vehicle Service Company Wang Mingcai.” (image below)
This meeting is important because Imre Gyuk and Gary Yang are together, in China in 2018. The year after the Dept of Energy license given to Gary Yang was unlawfully sublicensed to the Chinese.
NPR is correct in that U.S. taxpayers funded six years of research and development for vanadium redox flow batteries (2006-2012), and once the product was successful the technology was transferred to China (2014-2017) as part of the commercial manufacture. However, it was Gary Yang who gave it to them, and by all appearances he did so unlawfully.
There is going to be much more to this story…. Much more. We have only just begun to dig.
I have created this site to help people have fun in the kitchen. I write about enjoying life both in and out of my kitchen. Life is short! Make the most of it and enjoy!
This is a library of News Events not reported by the Main Stream Media documenting & connecting the dots on How the Obama Marxist Liberal agenda is destroying America
Centinel2012 